Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE VC W CODEINE versus TRINALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE VC W CODEINE versus TRINALIN.
PROMETHAZINE VC W/ CODEINE vs TRINALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine, which acts as a mu-opioid receptor agonist inhibiting ascending pain pathways and altering pain perception. Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, suppresses cough reflex via central action, and has anticholinergic, sedative, and antiemetic effects. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction of nasal blood vessels, reducing congestion.
TRINALIN is a combination of azatadine, a first-generation antihistamine that antagonizes histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and reducing nasal congestion.
1-2 tablets orally every 4-6 hours as needed for cough and congestion. Maximum 12 tablets in 24 hours.
One tablet (azatadine 1 mg/pseudoephedrine 120 mg) orally every 12 hours. Not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Promethazine: 9-16 hours (range 7-20 hours) in adults; codeine: 2.5-3.5 hours (terminal) with clinical considerations for prolonged effects in hepatic impairment and CYP2D6 poor metabolizers.
Terminal elimination half-life approximately 20-30 hours; clinical context: allows twice-daily dosing for sustained decongestant effect
Renal: 70-80% as unchanged promethazine and metabolites (including codeine and its glucuronides); biliary/fecal: 10-20%.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30%
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine/Decongestant